Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes

摘要

BackgroundEconomic models in oncology are commonly based on the three-state partitioned survival model (PSM) distinguishing between progression-free and progressive states. However, the heterogeneity of responses observed in immuno-oncology (I-O) suggests that new approaches may be appropriate to reflect disease dynamics meaningfully.